Download PDF
Viszeralchirurgie 2005; 40(4): 242-245
DOI: 10.1055/s-2005-836649
Originalarbeit

© Georg Thieme Verlag Stuttgart · New York

Wertigkeit der Positronenemissionstomographie für das Staging beim Ösophaguskarzinom

The Value of Positron Emission Tomography for Staging of Esophageal CancerP. Theissen1 , P. M. Schneider2 , M. Dietlein1 , A. H. Hölscher2 , H. Schicha1
  • 1Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln
  • 2Klinik und Poliklinik für Viszeral- und Gefäßchirurgie, Universität zu Köln
Further Information

Publication History

Publication Date:
13 September 2005 (online)

    Permissions and Reprints

Zusammenfassung

Der Wert der Positronenemissionstomographie mit 18F-18-Fluorodesoxyglukose (FDG-PET) für das primäre Staging und das posttherapeutische Restaging beim Ösophaguskarzinom wurde in verschiedenen aktuellen Studien untersucht. Die meisten Studien vergleichen die Ergebnisse der FDG-PET mit denen der Computertomographie und/oder der endoskopischen Ultraschalluntersuchung. Die verschiedenen Autoren stimmen darin überein, dass der klinische Einsatz der FDG-PET sowohl die Identifikation von Lymphknotenmetastasen als auch die von Metastasen in anderen Organen verbessert. Eine zunehmende Zahl von Untersuchern zeigte darüber hinaus die Aussagekraft der FDG-PET für die Analyse des Ansprechens des Ösophaguskarzinoms bei neoadjuvanter Radiochemotherapie sowie für die Vorhersage des Langzeitüberlebens.

Abstract

Positron emission tomography with 18F-Florodesoxyglucose (FDG-PET) was recently evaluated by several studies for staging and posttherapeutical re-staging of esophageal cancer. Most studies compared the FDG-PET results to CT and/or endoscopic ultrasonography. The different authors agreed that the use of FDG-PET improves the identification of lymph node metastases as well as of metastases in other organs. A growing number of investigators also showed the value of FDG-PET for the response analysis after neoadjuvant or concurrent radiochemotherapy resp. the prediction of the long-term survival.

Schlüsselwörter

Positronenemissionstomographie - PET - Ösophaguskarzinom - Staging

Key words

positron emission tomography - PET - esophageal cancer - staging

Literatur

  • 1 Dietlein M, Weber W, Schwaiger M, Schicha H. [18F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer].  Nuklearmedizin. 2003;  42 145-156
    PubMedGoogle Scholar
  • 2 Dehdashti F, Siegel B A. Neoplasms of the esophagus and stomach.  Semin Nucl Med. 2004;  34 198-208
    CrossrefPubMedGoogle Scholar
  • 3 Czernin J, Phelps M E. Positron emission tomography scanning: current and future applications.  Annu Rev Med. 2002;  53 89-112
    CrossrefPubMedGoogle Scholar
  • 4 Sciuk J, Hermann S, Franzius C. [Valence of F-18-FDG-PET in the diagnosis of malignant lymphoma].  Radiologe. 2002;  42 1000-1008
    CrossrefPubMedGoogle Scholar
  • 5 Schmidt M, Schmalenbach M, Jungehulsing M, Theissen P. et al . 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis.  Nuklearmedizin. 2004;  43 91-101
    PubMedGoogle Scholar
  • 6 Rosa F, Meimarakis G, Stahl A, Bumm R. et al . Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease.  Nuklearmedizin. 2004;  43 135-140
    PubMedGoogle Scholar
  • 7 Keppler J S. Federal regulations and reimbursement for PET.  J Nucl Med Technol. 2001;  29 173-179
    PubMedGoogle Scholar
  • 8 Reske S N, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, „Onko-PET III”, 21 July and 19 September 2000.  Eur J Nucl Med. 2001;  28 1707-1723
    Google Scholar
  • 9 Dietlein M, Schicha H. [Reimbursement of the PET in oncology in Europe: a questionnaire based survey].  Nuklearmedizin. 2003;  42 80-85
    PubMedGoogle Scholar
  • 10 Weber W A, Dietlein M, Hellwig D, Kirsch C M, Schicha H, Schwaiger M. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].  Nuklearmedizin. 2003;  42 135-144
    PubMedGoogle Scholar
  • 11 Block M I, Patterson G A, Sundaresan R S, Bailey M S. et al . Improvement in staging of esophageal cancer with the addition of positron emission tomography.  Ann Thorac Surg. 1997;  64 770-776
    CrossrefPubMedGoogle Scholar
  • 12 Choi J Y, Jang H J, Shim Y M, Kim K. et al . 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: Prognostic implications.  J Nucl Med. 2004;  45 1843-1850
    PubMedGoogle Scholar
  • 13 Choi J Y, Lee K H, Shim Y M, Lee K S. et al . Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET.  J Nucl Med. 2000;  41 808-815
    PubMedGoogle Scholar
  • 14 Flamen P, Lerut A, Cutsem E Van, De Wever W. et al . Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.  J Clin Oncol. 2000;  18 3202-3210
    PubMedGoogle Scholar
  • 15 Flanagan F L, Dehdashti F, Siegel B A, Trask D D. et al . Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.  AJR Am J Roentgenol. 1997;  168 417-424
    PubMedGoogle Scholar
  • 16 Kato H, Kuwano H, Nakajima M, Miyazaki T. et al . Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma.  Cancer. 2002;  94 921-928
    CrossrefPubMedGoogle Scholar
  • 17 Kim K, Park S J, Kim B T, Lee K S, Shim Y M. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography.  Ann Thorac Surg. 2001;  71 290-294
    CrossrefPubMedGoogle Scholar
  • 18 Westreenen H L van, Westerterp M, Bossuyt P M, Pruim J. et al . Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer.  J Clin Oncol. 2004;  22 3805-3812
    CrossrefPubMedGoogle Scholar
  • 19 Westreenen H L van, Heeren P A, Dullemen H M van, der Jagt E J van. et al . Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations.  J Gastrointest Surg. 2005;  9 54-61
    CrossrefPubMedGoogle Scholar
  • 20 Brucher B L, Weber W, Bauer M, Fink U. et al . Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.  Ann Surg. 2001;  233 300-309
    CrossrefPubMedGoogle Scholar
  • 21 Downey R J, Akhurst T, Ilson D, Ginsberg R. et al . Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.  J Clin Oncol. 2003;  21 428-432
    CrossrefPubMedGoogle Scholar
  • 22 Weber W A, Ott K, Becker K, Dittler H J. et al . Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.  J Clin Oncol. 2001;  19 3058-3065
    PubMedGoogle Scholar
  • 23 Weber W A, Ott K. Imaging of esophageal and gastric cancer.  Semin Oncol. 2004;  31 530-541
    PubMedGoogle Scholar
  • 24 Theissen P, Schneider P M, Baldus S E, Jost A. et al . Monitoring of tumor response to neoadjuvant radio-chemotherapy of esophageal carcinoma by F-18-FDG-PET.  Chinese German J Clin Oncol. 2004;  3 257-262
    PubMedGoogle Scholar
  • 25 Fleming I D, Phillips J L, Menck H R, Murphy G P, Winchester D P. The National Cancer Data Base report on recent hospital cancer program progress toward complete American Joint Committee on Cancer/TNM staging.  Cancer. 1997;  80 2305-2310
    CrossrefPubMedGoogle Scholar
  • 26 Lerut T, Flamen P, Ectors N, Cutsem E Van. et al . Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy.  Ann Surg. 2000;  232 743-752
    CrossrefPubMedGoogle Scholar
  • 27 Kato H, Miyazaki T, Nakajima M, Takita J. et al . The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.  Cancer. 2005;  103 148-156
    CrossrefPubMedGoogle Scholar
  • 28 Flamen P, Lerut A, Cutsem E, Cambier J P. et al . The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.  J Thorac Cardiovasc Surg. 2000;  120 1085-1092
    CrossrefPubMedGoogle Scholar
  • 29 Kole A C, Plukker J T, Nieweg O E, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy.  Br J Cancer. 1998;  78 521-527
    PubMedGoogle Scholar
  • 30 Meltzer C C, Luketich J D, Friedman D, Charron M. et al . Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.  Clin Nucl Med. 2000;  25 882-887
    CrossrefPubMedGoogle Scholar
  • 31 Rankin S C, Taylor H, Cook G J, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma.  Clin Radiol. 1998;  53 659-665
    PubMedGoogle Scholar
  • 32 Jager P L, Que T H, Vaalburg W, Pruim J, Elsinga P, Plukker J T. Carbon-11 choline or FDG-PET for staging of oesophageal cancer?.  Eur J Nucl Med. 2001;  28 1845-1849
    CrossrefPubMedGoogle Scholar
  • 33 Junginger T, Kneist W, Schreckenberger M, Menzel C, Oberholzer K, Bartenstein P. [Positron emission tomography for the preoperative staging of esophageal carcinoma].  Dtsch Med Wochenschr. 2002;  127 1935-1941
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Wren S M, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer.  Arch Surg. 2002;  137 1001-1006
    PubMedGoogle Scholar
  • 35 Yoon Y C, Lee K S, Shim Y M, Kim B T, Kim K, Kim T S. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study.  Radiology. 2003;  227 764-770
    PubMedGoogle Scholar
  • 36 Westreenen H L van, Heeren P A, Jager P L, Dullemen H M van, Groen H, Plukker J T. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography.  Ann Surg Oncol. 2003;  10 1100-1105
    CrossrefPubMedGoogle Scholar
  • 37 Eloubeidi M A, Wallace M B, Hoffman B J, Leveen M B. et al . Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography.  Ann Thorac Surg. 2001;  72 212-219
    CrossrefPubMedGoogle Scholar
  • 38 Hulscher J B, Buskens C J, Bergman J J, Fockens P, Lanschot J J V, Obertop H. Positive peritruncal nodes for esophageal carcinoma. not always a dismal prognosis.  Dig Surg. 2001;  18 98-101
    CrossrefPubMedGoogle Scholar
  • 39 Minn H, Leskinen-Kallio S, Lindholm P, Bergman J. et al . [18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin.  J Comput Assist Tomogr. 1993;  17 115-123
    PubMedGoogle Scholar
  • 40 Hölscher A H, Metzger R, Schneider P M. [Preoperative radiochemotherapy of esophageal carcinoma. Light at the end of the tunnel?].  Zentralbl Chir. 2000;  125 319-325
    PubMedGoogle Scholar
  • 41 Kies M S, Rosen S T, Tsang T K, Shetty R. et al . Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer.  Cancer. 1987;  60 2156-2160
    PubMedGoogle Scholar
  • 42 Law S, Fok M, Chow S, Chu K M, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial.  J Thorac Cardiovasc Surg. 1997;  114 210-217
    PubMedGoogle Scholar
  • 43 Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux P, Raemdonck D Van. Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies.  Surg Oncol. 2001;  10 113-122
    CrossrefPubMedGoogle Scholar
  • 44 Luketich J D, Schauer P, Urso K, Kassis E. et al . Future directions in esophageal cancer.  Chest. 1998;  113 (Suppl 1) 120S-122S
    PubMedGoogle Scholar
  • 45 Urba S G, Orringer M B, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.  J Clin Oncol. 2001;  19 305-313
    PubMedGoogle Scholar
  • 46 Flamen P, Cutsem E, Lerut A, Cambier J P. et al . Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.  Ann Oncol. 2002;  13 361-368
    CrossrefPubMedGoogle Scholar
  • 47 Couper G W, Park K G. Detection of response to neoadjuvant therapy of esophageal squamous cell carcinoma by positron emission tomography (PET).  Ann Surg. 2003;  237 289-290
    PubMedGoogle Scholar
  • 48 Wieder H A, Brucher B L, Zimmermann F, Becker K. et al . Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.  J Clin Oncol. 2004;  22 900-908
    CrossrefPubMedGoogle Scholar
  • 49 Swisher S G, Erasmus J, Maish M, Correa A M. et al . 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.  Cancer. 2004;  101 1776-1785
    CrossrefPubMedGoogle Scholar
  • 50 Luketich J D, Friedman D M, Weigel T L, Meehan M A. et al . Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.  Ann Thorac Surg. 1999;  68 1133-1136
    CrossrefPubMedGoogle Scholar

Dr. Peter Theissen

Klinik und Poliklinik für Nuklearmedizin · Klinikum der Universität zu Köln

Kerpener Str. 62

50924 Köln

Germany

Phone: 02 21/4 78 58 56

Fax: 02 21/4 78 67 77

Email: peter.theissen@uni-koeln.de